Symic Bio, has completed enrolment for the SHIELD clinical trial of SB-030 in peripheral artery disease. The trial will evaluate the safety and efficacy of SB-030, a locally administered single-use therapeutic, in the reduction of restenosis following angioplasty.
“We are pleased to have reached this critical development milestone for SB-030,” said Nathan Bachtell, chief medical officer of Symic Bio. “SB-030 represents a pioneering matrix biology approach for addressing restenosis after vascular interventions, a prevalent and costly complication that is inadequately addressed by current therapies. We look forward to top-line results from this proof-of-concept study in the fourth quarter of 2017.”
“Completion of enrolment of the SHIELD trial is very encouraging,” stated Michael Conte, professor and chief of the Division of Vascular & Endovascular Surgery at the University of California, San Francisco (UCSF), USA, and co-director of the UCSF Center for Limb Preservation. “If successful, positive proof-of-concept results will pave the way for additional studies of SB-030 in endovascular and surgical indications.”